Catalyst overview
Research summary
This catalyst tracks a Phase 1/2 update for AMT-191 in Fabry disease. The expected timing is based on the latest available company guidance and may change.
07/29/26:- Ph1/2 data updated; liver enzyme toxicities resolved by May 2026; mid/high dosing remains paused.
Verification
Confirm timing and program details against the company announcement or filing.